April 27, 2023 by admin aurigene Combination efficacy and safety profile of an orally bioavailable small molecule agent targeting CD47/SIRPα axis (CD47 antagonists)
April 27, 2023 by admin aurigene Efficacy and safety profile of AU7R-104, a small molecule targeting CD47/SIRPα pathway
April 27, 2023 by admin aurigene AUR103 an oral small molecule CD47 antagonist in combination with azacytidine and bortezomib exhibits potent anti-tumor activity in myeloma and leukemia models in vitro and in
April 27, 2023 by admin aurigene ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity
April 18, 2023 by admin aurigene Characterization of the anti-tumor immune activation potential of AUR107, a novel small molecule p300/CBP bromodomain inhibitor SITC, Nov 2022
December 8, 2022 by Aurigene Tech Team Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer Nature 2022,434–439
November 9, 2022 by Aurigene Tech Team PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy
November 9, 2022 by Aurigene Tech Team Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development
November 15, 2022 by Aurigene Tech Team Safety, tolerability, pharmacokinetics and pharmacodynamics of AUR101, An RORγt inhibitor, in normal healthy volunteers
November 15, 2022 by Aurigene Tech Team Discovery and clinical development of the first small molecule checkpoint inhibitor for cancer therapy
